Active Biotech » Redeye: Active Biotech Q4 2022: Laquinimod Ready for Phase II 2023-02-09

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-functional	12 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". It does not store any personal data.
cookielawinfo-checkbox-necessary	12 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". It does not store any personal data.
CookieLawInfoConsent	12 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy	12 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.